RxDoctor Payments Data

Daniel Sackett, MD

Urology · Berlin, VTNPI 1952510372

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Astellas Pharma US Inc at 37.1% of the total. Reporting peaked in 2019 at $514 and has fallen 65.0% since, to $180 in 2021.

$994in general payments, 2019–2025

Across 53 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$369
  • AbbVie$74
  • Axogen$64
  • Johnson & Johnson$56
  • Dendreon Pharmaceuticals LLC$53
  • Tolmar Pharmaceuticals, Inc.$52
  • plus $326 from 14 others

What the payments were for

  • Food & beverage$98699%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$994 in reported general payments places this provider in the 80th percentile of 31 urology providers in Vermont.

See all urology providers in Vermont

Medicare billing

Part B allowed, 2024
$62,379
Medicare patients
340
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron52$39,518
LithostatAcetohydroxamic Acid12$10,447
Tadalafil16$8,888
Tamsulosin Hcl341$6,115
Potassium Citrate ErPotassium Citrate40$3,881
Finasteride158$2,272
Alfuzosin Hcl ErAlfuzosin Hcl96$1,832
Trospium Chloride29$1,461
Estradiol14$1,413
Solifenacin Succinate27$1,038
NitrofurantoinNitrofurantoin Macrocrystal20$795
Oxybutynin Chloride ErOxybutynin Chloride12$593
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$301
Allopurinol21$203
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$369$39,51852 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 urology providers in Vermont.

Other urology in Berlin

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →